公开(公告)号：US20090270445A1

公开(公告)日：2009-10-29

申请号：US12378195

申请日：2009-02-11

Applicant: Qingping Zeng ,  John G. Allen ,  Matthew P. Bourbeau ,  Celia Dominguez ,  Christopher H. Fotsch ,  Nianhe Han ,  Fang-Tsao Hong ,  Xin Huang ,  Matthew R. Lee ,  Aiwen Li ,  Qingyian Liu ,  James T. Rider ,  Seifu Tadesse ,  Andrew S. Tasker ,  Vellarkad N. Viswanadhan ,  Xianghong Wang ,  Kurt E. Weiler ,  George E. Wohlhieter ,  Guomin Yao ,  Chester Chenguang Yuan

Inventor： Qingping Zeng ,  John G. Allen ,  Matthew P. Bourbeau ,  Celia Dominguez ,  Christopher H. Fotsch ,  Nianhe Han ,  Fang-Tsao Hong ,  Xin Huang ,  Matthew R. Lee ,  Aiwen Li ,  Qingyian Liu ,  James T. Rider ,  Seifu Tadesse ,  Andrew S. Tasker ,  Vellarkad N. Viswanadhan ,  Xianghong Wang ,  Kurt E. Weiler ,  George E. Wohlhieter ,  Guomin Yao ,  Chester Chenguang Yuan

IPC: A61K31/427 ,  A61K31/437 ,  A61P35/00

CPC classification number: C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.

Abstract translation: 本发明涉及使用式I和式II的噻唑化合物及其组合物用于治疗由蛋白激酶B（PKB）介导的疾病，例如癌症和其它增殖性疾病，其中变量具有本文提供的定义。

公开(公告)号：US07148221B2

公开(公告)日：2006-12-12

申请号：US11195134

申请日：2005-08-01

Applicant: Elizabeth M. Doherty ,  Jiawang Zhu ,  Markian Stec ,  Mark H. Norman ,  Hui-Ling Wang ,  Christopher H. Fotsch ,  Ning Chen ,  Partha P. Chakrabarti ,  Celia Dominguez ,  James Richard Falsey ,  Christopher Hulme ,  Jodie Katon ,  Thomas Nixey ,  Vassil I. Ognyanov ,  Liping H. Pettus ,  Robert Michael Rzasa

Inventor： Elizabeth M. Doherty ,  Jiawang Zhu ,  Markian Stec ,  Mark H. Norman ,  Hui-Ling Wang ,  Christopher H. Fotsch ,  Ning Chen ,  Partha P. Chakrabarti ,  Celia Dominguez ,  James Richard Falsey ,  Christopher Hulme ,  Jodie Katon ,  Thomas Nixey ,  Vassil I. Ognyanov ,  Liping H. Pettus ,  Robert Michael Rzasa

IPC: C07D237/14 ,  C07D237/18 ,  C07D223/16 ,  C07D223/18 ,  A61K31/501 ,  A61P25/06

CPC classification number: C07D231/40 ,  C07D209/08 ,  C07D209/12 ,  C07D209/42 ,  C07D209/48 ,  C07D213/26 ,  C07D213/643 ,  C07D213/74 ,  C07D213/75 ,  C07D215/227 ,  C07D215/38 ,  C07D217/04 ,  C07D231/56 ,  C07D233/38 ,  C07D239/42 ,  C07D239/90 ,  C07D241/42 ,  C07D263/56 ,  C07D265/36 ,  C07D277/62 ,  C07D277/82 ,  C07D307/79 ,  C07D319/20 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

公开(公告)号：US20060040956A1

公开(公告)日：2006-02-23

申请号：US11234713

申请日：2005-09-23

Applicant: Guoqing Chen ,  Jeffrey Adams ,  Jean Bemis ,  Shon Booker ,  Guolin Cai ,  Lucian Di Pietro ,  Celia Dominguez ,  Daniel Elbaum ,  Julie Germain ,  Stephanie Geuns-Meyer ,  Michael Handley ,  Qi Huang ,  Joseph Kim ,  Tae-Seong Kim ,  Alexander Kiselyov ,  Xiaohu Ouyang ,  Vinod Patel ,  Leon Smith ,  Markian Stec ,  Andrew Tasker ,  Ning Xi ,  Shimin Xu ,  Chester Yuan ,  Michael Croghan

Inventor： Guoqing Chen ,  Jeffrey Adams ,  Jean Bemis ,  Shon Booker ,  Guolin Cai ,  Lucian Di Pietro ,  Celia Dominguez ,  Daniel Elbaum ,  Julie Germain ,  Stephanie Geuns-Meyer ,  Michael Handley ,  Qi Huang ,  Joseph Kim ,  Tae-Seong Kim ,  Alexander Kiselyov ,  Xiaohu Ouyang ,  Vinod Patel ,  Leon Smith ,  Markian Stec ,  Andrew Tasker ,  Ning Xi ,  Shimin Xu ,  Chester Yuan ,  Michael Croghan

IPC: A61K31/506 ,  C07D403/02

CPC classification number: C07D213/82 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/00 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

公开(公告)号：US06958356B2

公开(公告)日：2005-10-25

申请号：US10098994

申请日：2002-03-13

Applicant: Patrick Y. Lam ,  Charles G. Clark ,  Celia Dominguez ,  John M. Fevig ,  Amy Qi Han ,  Renhua Li ,  Donald J. Pinto ,  James R. Pruitt ,  Mimi L. Quan

Inventor： Patrick Y. Lam ,  Charles G. Clark ,  Celia Dominguez ,  John M. Fevig ,  Amy Qi Han ,  Renhua Li ,  Donald J. Pinto ,  James R. Pruitt ,  Mimi L. Quan

IPC: C07D231/14 ,  C07D231/56 ,  C07D233/54 ,  C07D233/61 ,  C07D261/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  A61K31/42 ,  A61K31/415 ,  C07D231/00 ,  C07D235/04

CPC classification number: C07D413/14 ,  C07D231/14 ,  C07D231/56 ,  C07D261/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04

Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Abstract translation: 本申请描述了含氮杂芳族化合物及其式I的衍生物或其药学上可接受的盐形式，其中环D-E表示胍模拟物，其可用作因子Xa的抑制剂。

公开(公告)号：US5731439A

公开(公告)日：1998-03-24

申请号：US409303

申请日：1995-03-24

Applicant: David John Carini ,  Joseph Cacciola ,  Celia Dominguez ,  John Matthew Fevig

Inventor： David John Carini ,  Joseph Cacciola ,  Celia Dominguez ,  John Matthew Fevig

IPC: A61K38/00 ,  C07F5/02 ,  C07K5/06 ,  C07F5/04 ,  C07F5/05

CPC classification number: C07F5/025 ,  C07F5/02 ,  C07K5/06191 ,  A61K38/00

Abstract: The present invention relates generally to .alpha.-aminoboronic acids and corresponding peptide analogs in which the .alpha.-carbon is substituted with an optionally functionalized piperidine containing alkyl group. These compounds are useful as inhibitors of trypsin-like serine protease enzymes.

Abstract translation: 本发明一般涉及α-氨基硼酸和相应的肽类似物，其中α-碳被任选官能化的含哌啶烷基取代。 这些化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂。

公开(公告)号：US20170283436A1

公开(公告)日：2017-10-05

申请号：US15507208

申请日：2015-08-28

Applicant: Celia DOMINGUEZ ,  John WITYAK ,  Jonathan BARD ,  Alex KISELYOV ,  Christopher John BROWN ,  Sebastien Rene Gabriel GALAN ,  Michael Edward PRIME ,  Paul Richard GILES ,  Elise Luciennen Paulette GADOULEAU ,  Thomas Martin KRÜLLE ,  Daniel CLARKFREW ,  Peter David JOHNSON ,  Sabinc SCHAERTI ,  Steffen Kaspar GRIMM ,  Jan Dirk KAHMANN ,  Christoph SCHEICH ,  Samuel COE ,  Sarah HAYES ,  CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Alex Kiselyov ,  Christopher John Brown ,  Sébastien René Gabriel Galan ,  Michael Edward Prime ,  Paul Richard Giles ,  Elise Luciennen Paulette Gadouleau ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  Peter David Johnson ,  Samuel Coe ,  Sarah Hayes

IPC: C07D513/04 ,  C07D413/04 ,  C07D413/14 ,  A61K51/04 ,  C07D498/04 ,  C07D405/14 ,  C07D471/04 ,  C07D263/57 ,  C07D413/12

CPC classification number: C07D513/04 ,  A61K51/0455 ,  A61K51/0459 ,  A61K51/0463 ,  C07D263/57 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US09765054B2

公开(公告)日：2017-09-19

申请号：US13981107

申请日：2012-01-23

Applicant: Roland W. Bürli ,  Andrew J. Stott ,  Perla Breccia ,  Celia Dominguez ,  Ignacio Muñoz-Sanjuàn ,  Christopher A. Luckhurst ,  Samantha J. Hughes ,  Alan F. Haughan

Inventor： Roland W. Bürli ,  Andrew J. Stott ,  Perla Breccia ,  Celia Dominguez ,  Ignacio Muñoz-Sanjuàn ,  Christopher A. Luckhurst ,  Samantha J. Hughes ,  Alan F. Haughan

IPC: A61K31/415 ,  A61K31/505 ,  A61K31/519 ,  C07D231/12 ,  C07D239/26 ,  C07D319/08 ,  C07D487/04 ,  C07D401/06 ,  C07C259/08 ,  C07D205/04 ,  C07D207/10 ,  C07D209/44 ,  C07D209/46 ,  C07D209/82 ,  C07D211/58 ,  C07D211/70 ,  C07D213/56 ,  C07D213/74 ,  C07D215/18 ,  C07D233/61 ,  C07D237/08 ,  C07D263/32 ,  C07D265/36 ,  C07D267/14 ,  C07D277/30 ,  C07D295/155 ,  C07D317/46 ,  C07D319/18 ,  C07D401/04 ,  C07D409/08 ,  C07D413/04 ,  C07D417/08 ,  C07D471/04 ,  C07D491/10 ,  C07C311/14 ,  C07D233/64

CPC classification number: C07D401/06 ,  C07C259/08 ,  C07C311/14 ,  C07C2601/02 ,  C07C2601/14 ,  C07D205/04 ,  C07D207/10 ,  C07D209/44 ,  C07D209/46 ,  C07D209/82 ,  C07D211/58 ,  C07D211/70 ,  C07D213/56 ,  C07D213/74 ,  C07D215/18 ,  C07D231/12 ,  C07D233/61 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D263/32 ,  C07D265/36 ,  C07D267/14 ,  C07D277/30 ,  C07D295/155 ,  C07D317/46 ,  C07D319/18 ,  C07D401/04 ,  C07D409/08 ,  C07D413/04 ,  C07D417/08 ,  C07D471/04 ,  C07D487/04 ,  C07D491/10

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

公开(公告)号：US20160251318A1

公开(公告)日：2016-09-01

申请号：US14241374

申请日：2012-08-28

Applicant: Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

Inventor： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

IPC: C07D239/28 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D401/12 ,  C07D405/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10 ,  C07D413/04 ,  C07D471/04 ,  C07D409/04 ,  C07D417/04 ,  C07D403/10 ,  C07D405/10 ,  C07D401/04

CPC classification number: C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract translation: 本文提供了某些化学实体。 还提供了包含至少一种化学物质和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US08017601B2

公开(公告)日：2011-09-13

申请号：US11479187

申请日：2006-06-30

Applicant: Tae-Seong Kim ,  Jean-Christophe Harmange ,  Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Timothy S. Harvey ,  Joseph L. Kim ,  Matthew Lee ,  Longbin Liu ,  Vinod F. Patel ,  Andrew Tasker

Inventor： Tae-Seong Kim ,  Jean-Christophe Harmange ,  Steven Bellon ,  Shon Booker ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Timothy S. Harvey ,  Joseph L. Kim ,  Matthew Lee ,  Longbin Liu ,  Vinod F. Patel ,  Andrew Tasker

IPC: C07D403/02 ,  A61K31/538

CPC classification number: C07D333/38 ,  C07D217/02 ,  C07D217/24 ,  C07D401/10 ,  C07D401/12 ,  C07D409/12 ,  C07D417/10 ,  C07D417/12

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US20110118252A1

公开(公告)日：2011-05-19

申请号：US12945575

申请日：2010-11-12

Applicant: Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessandro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

Inventor： Tae-Seong Kim ,  David Bauer ,  Steven Bellon ,  Alessandro Boezio ,  Shon Booker ,  Deborah Choquette ,  Derin C. D'Amico ,  Noel D'Angelo ,  Celia Dominguez ,  Ingrid M. Fellows ,  Julie Germain ,  Russell Graceffa ,  Jean-Christophe Harmange ,  Satoko Hirai ,  Daniel La ,  Matthew Lee ,  Longbin Liu ,  Mark H. Norman ,  Michele Potashman ,  Philip Roveto ,  Aaron C. Siegmund ,  Ning Xi ,  Kevin Yang

IPC: A61K31/4709 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/496 ,  A61K31/501 ,  A61P35/00

CPC classification number: C07D413/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于预防和治疗诸如HGF介导的疾病等疾病是有效的。 本发明包括新颖的化合物，类似物，前药和药学上可接受的盐，用于预防和治疗疾病和其它疾病或涉及癌症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。